No Data
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Express News | Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo
Express News | Vistagen Therapeutics Inc: Ph15 Nasal Spray Demonstrates Statistically Significant Efficacy Versus Placebo and Caffeine
Express News | Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.